29 October 2022 in Annals of Thoracic Surgery Short Reports
Restrictive or hypertrophic cardiomyopathy presents a challenge to left ventricular assist device placement because of the small left ventricle cavity. Cases have described inflow cannulation of the HeartWare HVAD by expanded polytetrafluoroethylene conduit through the atrial septum to the left atrium. We applied this technique to an adult man with restrictive cardiomyopathy and pulmonary hypertension using the HeartMate 3, which successfully supported the patient and led to significant reduction in pulmonary artery pressure. He received a transplant 3 months later without complications. For select patients, left atrial conduit for HeartMate 3 inflow is a feasible alternative to conventional apical cannulation.
27 November 2017 in Clinical and Experimental Hypertension
Background: In the setting of metastatic RCC (mRCC), pazopanib is approved as first line therapy. Unfortunately treatment may lead to cardiotoxicity such as hypertension, heart failure, and myocardial ischemia. Objective: Define the in vivo role of pazopanib in the development of cardiotoxicity. Methods: Wild type mice were dosed for 42 days via oral gavage, and separated into control and treatment (pazopanib) groups. Baseline ECG’s, echocardiograms, and blood pressures were recorded. At the conclusion of the study functional parameters were again recorded, and animals were used for pathological, histological, and protein analysis. Results: After 2 weeks of dosing with pazopanib, the treatment group exhibited a statistically significant increase in mean arterial pressure compared to control mice (119 ± 11.7 mmHg versus 108 ± 8.2 mmHg, p = 0.049). Treatment with pazopanib led to a significant reduction in the cardiac output of mice. Conclusion: Our findings in mice clearly demonstrate that treatment with pazopanib leads to a significant elevation in blood pressure after 2 weeks of dosing and this persists for the duration of dosing. The continued development of the cardio-oncology field will be paramount in providing optimal oncologic care while simultaneously improving cardiac outcomes through further investigation into the mechanisms of CV toxicity.
25 November 2022 in Clinical Transplantation
5 September 2024 in Artificial Organs